GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIA Pharmaceuticals Inc (GREY:VIAP) » Definitions » LT-Debt-to-Total-Asset

VIA Pharmaceuticals (VIA Pharmaceuticals) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2010)


View and export this data going back to 1998. Start your Free Trial

What is VIA Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. VIA Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Dec. 2010 was 0.00.

VIA Pharmaceuticals's long-term debt to total assets ratio stayed the same from Dec. 2009 (0.00) to Dec. 2010 (0.00).


VIA Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for VIA Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIA Pharmaceuticals LT-Debt-to-Total-Asset Chart

VIA Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

VIA Pharmaceuticals Quarterly Data
Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

VIA Pharmaceuticals LT-Debt-to-Total-Asset Calculation

VIA Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2010 is calculated as

LT Debt to Total Assets (A: Dec. 2010 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2010 )/Total Assets (A: Dec. 2010 )
=0/0.5
=

VIA Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2010 is calculated as

LT Debt to Total Assets (Q: Dec. 2010 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2010 )/Total Assets (Q: Dec. 2010 )
=0/0.5
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VIA Pharmaceuticals  (GREY:VIAP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


VIA Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of VIA Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


VIA Pharmaceuticals (VIA Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
750 Battery Street, Suite 330, San Francisco, CA, USA, 94111
VIA Pharmaceuticals Inc is a development stage biotechnology company focuses on the development of small-molecule drugs to treat cardiovascular and metabolic diseases.
Executives
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv, L.p. 10 percent owner 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Management Iv Llc 10 percent owner 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv Co Invesment Fund Lp 10 percent owner 750 BATTERY ST STE 400, SAN FRANCISCO CA 94111
Bay City Capital Llc 10 percent owner 750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111
Douglas B Given director C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Karen Steil Wright officer: V.P. ? Finance, Controller 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Lawrence Kenneth Cohen director, officer: CEO and President 750 BATTERY STREET, SUITE 330 SAN FRANCISCO CA 94111
Richard L Anderson director 14031 216TH WAY NE, WOODINVILLE WA 98072
Mark Bagnall director 3876 BAY CENTER PLACE, HAYWARD CA 94545
Rebecca Taub officer: SVP, Research & Development 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Adeoye Y Olukotun officer: Chief Medical Officer 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Deerfield Special Situations Fund International Ltd 10 percent owner, other: Possible Member of 10% Group BISON COURT, ROAD TOWN, TORTOLA D8 -
Deerfield Special Situations Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

VIA Pharmaceuticals (VIA Pharmaceuticals) Headlines

From GuruFocus